Long Ideas - Keryx Biopharmaceuticals (NASDAQ:KERX) announced Monday morning that its Japanese development partner JT Tori Pharmaceutical Co. submitted a new drug application (NDA) for Zerenex, the company’s … Continue Reading
Read NowMost Popular - In a comment to Swiss newspaper SonntagsZeitung, Roche (OTC:RHBBY) Chairman Franz Humerstated said that a hostile bid for Illumina (NASDAQ:ILMN) is “off the table,” which … Continue Reading
Read NowMost Popular - A catalyst-rich 2013 and a solid financial position for BioMarin should push the stock higher. Since we published this story on Monday, shares of the drug … Continue Reading
Read NowMost Popular - Synageva (NASDAQ:GEVA) announced its third stock offering in twelve months on Thursday, which after a pricing update, should raise approximately $90M for pipeline development, particularly … Continue Reading
Read NowMost Popular - Keryx Biopharmaceuticals (KERX) issued a press release on Thursday morning related to the Medicare bundle for oral-only phosphate binders, which would positively impact the company’s lead candidate … Continue Reading
Read NowMost Popular - Following the Phase III failure of Oncothyreon’s lead candidate Stimuvax, we see some value remaining in the oncology developer. The company has a few options … Continue Reading
Read NowLong Ideas - Happy Holidays from the team at PropThink! Our report on Trius Therapeutics tackled the short thesis, repudiating the focal points of the bear argument. Shares are, … Continue Reading
Read Now